Panosome GmbH

🚀 Panosome GmbH Awarded 2nd Research Grant of 1.8 Million Euros! 🚀 We are excited to share that Panosome GmbH, in collaboration with our partner the DKFZ German Cancer Research Center, has been awarded a substantial grant to advance our innovative brain cancer therapeutic. This significant funding of more than 2.7 M Euros by the Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) includes a direct allocation of 1.8 M Euros to Panosome. The new GliomAb grant marks our second major public funding achievement this year, following the CarboVAST grant for pancreatic cancer therapy awarded in May. Combined, these grants inject over 3.3 million Euros directly into Panosome, empowering us to accelerate the development of transformative cancer treatments that address critical medical needs. Together with our dedicated team and partners, we're forging a path towards a brighter future in cancer therapy. Stay tuned for more updates as we continue our mission to innovate and improve patient outcomes. #Braincancertherapy #Innovation #ScientificExcellence #PanosomeGmbH #Biotech #DKFZ

𝗔𝗹𝗺𝗼𝘀𝘁 𝘁𝘄𝗼 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗲𝘂𝗿𝗼𝘀 𝗳𝗼𝗿 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝘀𝘁𝗮𝗿𝘁-𝘂𝗽: Panosome GmbH, a biotech company founded in Heidelberg in 2020, specializes in the development of monoclonal antibodies for a wide range of medical purposes. The basis for this is the VAST technology platform jointly developed by Panosome and DKFZ. Panosome now wants to use the VAST technology to develop antibodies for the treatment of pancreatic cancer. The Federal Ministry of Education and Research is supporting this project with a total of 1.99 million euros as part of its "KMU-innovativ: Biomedicine" funding measure. Panosome will receive funding totaling 1.55 million euros and the DKFZ 446 thousand euros. 𝗕𝗠𝗕𝗙 𝗳𝘂𝗻𝗱𝘀 𝗗𝗞𝗙𝗭 𝘀𝗽𝗶𝗻-𝗼𝗳𝗳 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗮𝗻 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿: https://lnkd.in/ense6wSY DKFZ Deutsches Krebsforschungszentrum, Nina Papavasiliou

📣 Revolutionizing Cancer Treatment: Panosome GmbH Receives Major Funding from BMBF for Antibody Therapy Development! 🚀 The Federal Ministry of Education and Research, Germany (BMBF) is funding the DKFZ German Cancer Research Center spin-off Panosome GmbH with nearly two million euros for the development of an antibody therapy against pancreatic cancer. 🔬 Founded in 2020 in #Heidelberg, Panosome GmbH specializes in monoclonal #antibodies using the advanced #VAST technology platform. With this #funding, they will focus on targeting MUC-1, a marker in 90% of malignant pancreatic tumors. This initiative, under the "KMU-innovativ: Biomedizin" program, will provide 1.55 million euros to Panosome and 446 thousand euros to DKFZ. 🙌 Dr. Jens Brandenburg highlights the rapid evolution in medical biotechnology and its potential in treating pancreatic cancer, a disease often diagnosed too late. "Supporting SMEs in biotechnology is crucial for advancing drug development and quickly translating research into patient care," he said. Prof. Dr. Nina Papavasiliou, our Managing Director, says, "The BMBF funding is a milestone for Panosome, enabling us to leverage our technology for cancer patients' benefit." 🌟 This project, CarboVAST, showcases the promising collaboration between research and application. The VAST technology aims to develop effective antibodies against not just pancreatic cancer but potentially other cancers like breast, ovarian, and lung cancer. 🎉 Congratulations to Panosome GmbH and their team! #Biotech #Innovation #Healthcare #DKFZ #Panosome #BMBF #HeidelbergFundingAlert

𝑾𝒆 𝒂𝒓𝒆 𝒈𝒓𝒂𝒕𝒆𝒇𝒖𝒍 𝒕𝒐 𝒘𝒆𝒍𝒄𝒐𝒎𝒆 𝒂𝒏𝒐𝒕𝒉𝒆𝒓 𝒏𝒆𝒘 𝒎𝒆𝒎𝒃𝒆𝒓 𝒕𝒐 𝒐𝒖𝒓 𝒏𝒆𝒕𝒘𝒐𝒓𝒌🌍 ⭐ Happy to welcome Panasome! Panosome GmbH uses its novel, proprietary technology platform to generate antibodies to challenging disease targets. The VAST technology platform unlocks antibodies to small molecules, peptides, and proteins and the high on-target specificity of Panosome's antibodies limits side effects. They focus their development pipeline on cancer indications with a very high medical need. For this, Panasome generates monoclonal antibodies against tumor-specific carbohydrates (such as MUC1) to target pancreatic cancer that expresses aberrantly glycosylated MUC-1 and a T cell receptor-like antibodies to target intracellular cancer antigens displayed on antigenic presenting cells. Panasome applies this concept to specifically target a mutation connected to the rare disease midline glioma, an aggressive brain cancer that predominantly affects children. If you want to learn more about Panasome´s new path to immunity, contact Dr. Sebastian Kruse and Nina Papavasiliou We are looking forward to see your active participation in the network!

Happy to have Katharina represent Panosome at #CIMT2024 last week! It was an overall amazing conference and we’re looking forward to the next one! 🔬

Find all the details for the CarboVAST grant in Panosome's and DKFZ's joint press release

🌟 Panosome GmbH Awarded €1.55 Million Research Grant!🌟 We are thrilled to announce that Panosome GmbH together with our partner the German Cancer Research Center has received a nearly 2 M EUR research grant to advance our groundbreaking work in cancer medicine. Today, Secretary of State Dr. Jens Brandenburg visited Panosome GmbH to personally hand over the grant notice. This funding marks a significant milestone in our journey towards effective therapeutics for pancreas cancer. To mark the occasion, a syndicate from members of Encourage Ventures e.V. has announced their commitment to invest in Panosome. We are looking forward to the collaboration! Read our full press release to learn more about this exciting development! #Innovation #ScientificExcellence #PanosomeGmbH #Biotech

Panosome is extremely proud to attend and support the 25th #EMBL PhD Symposium in Heidelberg as a sponsor! Great science all around, accompanied by the the feeling of community and the Power of Many - come by our booth to learn more on how a parasite can be a „Power of Many“ in mounting robust antibody responses against small molecules! #EMBLPhDSymposium #PowerOfMany #EMBL #CollectiveBehaviour #PhD #panosomeGmbH